Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating

On June 3, Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while keeping an Overweight rating on the shares. The firm adjusted its price target after management lowered its EPS outlook for 2025.

The company reported fiscal second-quarter results on May 1, with revenue increasing 4.5% year-over-year to $5.3 billion. Despite the growth, revenue missed the consensus by $80.64 million.

A surgeon performing a procedure in an operating room using a medical device supplied by the company.

Becton, Dickinson, and Company (NYSE:BDX) is facing the impact of tariffs and management estimates it to be around $0.25 per share for the fiscal year 2025. As a result, the company reduced its full-year EPS outlook from a range of $14.30 to $14.60 to a range of $14.06 to $14.34.

Becton, Dickinson, and Company (NYSE:BDX) is a global medical technology company that develops, manufactures, and sells a broad range of medical supplies. It operates through three main business segments including BD Medical, BD Life Sciences, and BD interventional.

While we acknowledge the potential of BDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BDX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.